Integra LifeSciences [IART] vs Stryker [SYK] Detailed Stock Comparison
TLDR: Quick Comparison Summary
Based on 21 vital metrics comparison: Integra LifeSciences Holdings Corporation wins in 5 metrics, Stryker Corporation wins in 15 metrics, with 0 ties. Stryker Corporation appears stronger overall.
View Metrics Details
Vital Metrics Comparison
| Metric | Integra LifeSciences Holdings Corporation | Stryker Corporation | Better |
|---|---|---|---|
| P/E Ratio (TTM) | 66.48 | 39.21 | Stryker Corporation |
| Price-to-Book Ratio | 0.79 | 5.62 | Integra LifeSciences Holdings Corporation |
| Debt-to-Equity Ratio | 195.01 | 72.97 | Stryker Corporation |
| PEG Ratio | -0.61 | 0.72 | Stryker Corporation |
| EV/EBITDA | 8.70 | 19.90 | Integra LifeSciences Holdings Corporation |
| Profit Margin (TTM) | -31.58% | 12.92% | Stryker Corporation |
| Operating Margin (TTM) | 12.44% | 27.24% | Stryker Corporation |
| EBITDA Margin (TTM) | 12.44% | 27.24% | Stryker Corporation |
| Return on Equity | -39.90% | 15.08% | Stryker Corporation |
| Return on Assets (TTM) | 2.39% | 7.92% | Stryker Corporation |
| Free Cash Flow (TTM) | $-45.25M | $4.28B | Stryker Corporation |
| Dividend Yield | N/A | 0.97% | N/A |
| 1-Year Return | 46.13% | -17.25% | Integra LifeSciences Holdings Corporation |
| Price-to-Sales Ratio (TTM) | 0.50 | 5.02 | Integra LifeSciences Holdings Corporation |
| Enterprise Value | $2.59B | $138.30B | Stryker Corporation |
| EV/Revenue Ratio | 1.58 | 5.51 | Integra LifeSciences Holdings Corporation |
| Gross Profit Margin (TTM) | 50.78% | 64.54% | Stryker Corporation |
| Revenue per Share (TTM) | $21 | $66 | Stryker Corporation |
| Earnings per Share (Diluted) | $-6.74 | $8.40 | Stryker Corporation |
| Beta (Stock Volatility) | 1.07 | 0.93 | Stryker Corporation |
| Short % of Float | 15.66% | 1.20% | Stryker Corporation |
Integra LifeSciences Holdings Corporation vs Stryker Corporation Stock Performance Analysis
Loading Price Chart...
Performance Comparison
Short-term Returns
| Stock | 1D | 1W | 1M | 3M | 6M | YTD |
|---|---|---|---|---|---|---|
| Integra LifeSciences Holdings Corporation | -1.74% | 3.07% | 23.83% | 93.78% | 29.62% | 45.38% |
| Stryker Corporation | -1.36% | 2.13% | 0.38% | -11.91% | -13.33% | -11.56% |
Long-term Returns
| Stock | 1Y | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|
| Integra LifeSciences Holdings Corporation | 46.13% | -57.12% | -74.14% | -53.04% | -23.64% | -6.03% |
| Stryker Corporation | -17.25% | 6.06% | 22.47% | 172.95% | 440.98% | 592.85% |
Performance & Financial Health Analysis: Integra LifeSciences Holdings Corporation vs Stryker Corporation
| Metric | IART | SYK |
|---|---|---|
| Market Information | ||
| Market Cap | $804.31M | $126.25B |
| Market Cap Category | Small cap | Large cap |
| 10 Day Avg. Volume | 754,949 | 1,881,406 |
| 90 Day Avg. Volume | 818,793 | 2,161,139 |
| Last Close | $17.46 | $307.94 |
| 52 Week Range | $8.70 - $18.19 | $281.00 - $404.87 |
| % from 52W High | -4.01% | -23.94% |
| All-Time High | $77.40 (Apr 26, 2021) | $406.19 (Jan 27, 2025) |
| % from All-Time High | -77.44% | -24.19% |
| Growth Metrics | ||
| Quarterly Revenue Growth | -0.02% | 0.11% |
| Quarterly Earnings Growth | -0.02% | 0.56% |
| Financial Health | ||
| Profit Margin (TTM) | -0.32% | 0.13% |
| Operating Margin (TTM) | 0.12% | 0.27% |
| Return on Equity (TTM) | -0.40% | 0.15% |
| Debt to Equity (MRQ) | 195.01 | 72.97 |
| Cash & Liquidity | ||
| Book Value per Share (MRQ) | $13.40 | $58.61 |
| Cash per Share (MRQ) | $3.38 | $10.71 |
| Operating Cash Flow (TTM) | $50.38M | $5.04B |
| Levered Free Cash Flow (TTM) | $44.46M | $4.17B |
| Dividends | ||
| Last 12-Month Dividend Yield | N/A | 0.97% |
| Last 12-Month Dividend | N/A | $3.40 |
Valuation & Enterprise Metrics Analysis: Integra LifeSciences Holdings Corporation vs Stryker Corporation
| Metric | IART (Apr 24, 2026) | SYK (Apr 24, 2026) |
|---|---|---|
| Price Ratios | ||
| P/E Ratio (TTM) | 66.48 | 39.21 |
| Forward P/E | 4.11 | 19.67 |
| PEG Ratio | -0.61 | 0.72 |
| Price to Sales (TTM) | 0.50 | 5.02 |
| Price to Book (MRQ) | 0.79 | 5.62 |
| Market Capitalization | ||
| Market Capitalization | $804.31M | $126.25B |
| Enterprise Value | $2.59B | $138.30B |
| Enterprise Value Metrics | ||
| Enterprise to Revenue | 1.58 | 5.51 |
| Enterprise to EBITDA | 8.70 | 19.90 |
| Risk & Other Metrics | ||
| Beta | 1.07 | 0.93 |
| Book Value per Share (MRQ) | $13.40 | $58.61 |
Financial Statements Comparison: Integra LifeSciences Holdings Corporation vs Stryker Corporation
Financial Metrics
Loading Financial Charts...
Revenue
Operating Margin
Profit Margin
Long Term Debt
Income Flow Analysis
Financial Statements Comparison
Income Statement
| Metric | IART (2025) | SYK (2025) |
|---|---|---|
| Revenue/Sales | 1.64B | 25.12B |
| Cost of Goods Sold | 803.63M | 9.05B |
| COGS % of Revenue | 49.1% | 36.0% |
| Gross Profit | 831.62M | 16.07B |
| Gross Margin | 50.9% | 64.0% |
| Research & Development | 98.97M | 1.62B |
| Operating Income (EBIT) | 18.00M | 5.06B |
| Operating Margin | 1.1% | 20.1% |
| EBITDA | 185.95M | 6.48B |
| EBITDA Margin | 11.4% | 25.8% |
| Pre-Tax Income | -563.50M | 4.51B |
| Pre-Tax Income % of Revenue | -34.5% | 18.0% |
| Income Tax | -47.03M | 1.27B |
| Income Tax % of Revenue | -2.9% | 5.0% |
| Net Income (Profit) | -516.47M | 3.25B |
| Profit Margin | -31.6% | 12.9% |
Balance Sheet & Liquidity Metrics
| Metric | IART (2025) | SYK (2025) |
|---|---|---|
| Cash & Equivalents | 235.05M | 4.01B |
| Total Current Assets | 1.16B | 14.76B |
| Total Current Assets % of Revenue | 70.9% | 58.7% |
| Total Current Liabilities | 455.98M | 7.79B |
| Total Current Liabilities % of Revenue | 27.9% | 31.0% |
| Long-Term Debt | 1.89B | 14.86B |
| Long-Term Debt % of Revenue | 115.7% | 59.2% |
| Total Shareholders Equity | 1.04B | 22.42B |
| Retained Earnings | 423.44M | 20.47B |
| Retained Earnings % of Revenue | 25.9% | 81.5% |
| Property, Plant & Equipment | 140.57M | 1.79B |
Cash Flow Statement Comparison
| Metric | IART (2025) | SYK (2025) |
|---|---|---|
| Operating Cash Flow | -458.67M | 4.70B |
| Operating Cash Flow % of Revenue | -28.0% | 18.7% |
| Capital Expenditures | -81.44M | -761.00M |
| Free Cash Flow | -45.25M | 4.28B |
| FCF Margin | -2.8% | 17.1% |
| Debt Repayment | -669.89M | -1.40B |
| Common Stock Repurchase | -221,000 | N/A |
Short Interest & Institutional Ownership Analysis
| Metric | IART | SYK |
|---|---|---|
| Shares Short | 8.86M | 4.42M |
| Short Ratio | 10.73 | 1.95 |
| Short % of Float | 15.66% | 1.20% |
| Shares Outstanding | 77.89M | 382.50M |
| Float Shares | 58.96M | 346.55M |
| % Held by Insiders | 14.38% | 5.37% |
| % Held by Institutions | 97.96% | 82.09% |
| % Held by Public | -12.34% | 12.54% |
Dividend Analysis & Yield Comparison: Integra LifeSciences Holdings Corporation vs Stryker Corporation
| Metric | IART | SYK |
|---|---|---|
| Last 12-Month Dividend | N/A | $3.40 |
| Last 12-Month Dividend Yield | N/A | 0.97% |
| 3-Year Avg Annual Dividend | N/A | $3.23 |
| 3-Year Avg Dividend Yield | N/A | 0.24% |
| 3-Year Total Dividends | N/A | $9.69 |
| Ex-Dividend Date | N/A | Dec 31, 2025 |